![Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection | Nature Communications Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-33826-4/MediaObjects/41467_2022_33826_Fig1_HTML.png)
Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection | Nature Communications
![Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial - The Lancet Oncology Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/a3903ead-3066-41a8-9953-161d09384c00/gr1.jpg)
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial - The Lancet Oncology
![The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis | Health and Quality of Life Outcomes | Full Text The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis | Health and Quality of Life Outcomes | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12955-019-1220-z/MediaObjects/12955_2019_1220_Fig3_HTML.png)
The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis | Health and Quality of Life Outcomes | Full Text
![Frontiers | Consensus Guidelines for Improving Quality of Assessment and Training for Neuromuscular Diseases Frontiers | Consensus Guidelines for Improving Quality of Assessment and Training for Neuromuscular Diseases](https://www.frontiersin.org/files/Articles/735936/fgene-12-735936-HTML-r1/image_m/fgene-12-735936-g001.jpg)
Frontiers | Consensus Guidelines for Improving Quality of Assessment and Training for Neuromuscular Diseases
![Current Oncology | Free Full-Text | CRAFT—A Proposed Framework for Decentralized Clinical Trials Participation in Canada Current Oncology | Free Full-Text | CRAFT—A Proposed Framework for Decentralized Clinical Trials Participation in Canada](https://www.mdpi.com/curroncol/curroncol-28-00329/article_deploy/html/images/curroncol-28-00329-g001.png)
Current Oncology | Free Full-Text | CRAFT—A Proposed Framework for Decentralized Clinical Trials Participation in Canada
![Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension | Nature Medicine Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-1034-x/MediaObjects/41591_2020_1034_Fig1_HTML.png)